The journey started with an enigma in the zebrafish embryo: some endothelial cells, actively involved in the initial stages ...

The company plans to announce Phase 1b interim data by mid-2026, and the TENACITY-01 study is expected to be completed by late 2028. This timing enables progression to Phase 2 evaluation following ...

Using drugs that inhibit enzymes called CDK4/6 and CDK2 extends the G1 phase of the cell cycle and helps to slow the growth of drug-resistant breast cancer.

A new study published in Science Translational Medicine by researchers at The University of Texas MD Anderson Cancer Center ...

A new study published today in Science Translational Medicine by researchers at The University of Texas MD Anderson Cancer ...

Researchers used miniature human brains grown in the lab to uncover why certain genetic mutations lead to abnormally small ...

Volkswagen's battery division PowerCo has commissioned its Salzgitter plant as planned and produced the first unified cells. Production of the PowerCo unified ...

Pluri, Inc. (“Pluri”, the “Company”, “we” or “us”) (Nasdaq, TASE: PLUR), a leading biotechnology company leveraging its proprietary platform for cell-based solutions through a collaborative network of ...

The anti-CD40 antibody tegoprubart offers a tacrolimus-free immunosuppression option for preventing islet transplant ...

CBD and THC kill ovarian cancer cells at doses that largely spare normal cells, disrupting survival pathways through multiple ...

ASH 2025 highlighted innovative cancer treatments, including in vivo CAR T therapy and options that enhance quality of life ...